Table 2.
Exposure | Menstrual cycles |
Pregnancies |
Unadjusted |
Adjusteda |
||||||
---|---|---|---|---|---|---|---|---|---|---|
N | n (%) exposed | N | n (%) exposed | FR (95% CI) | FR (95% CI) | |||||
Primary analysis | ||||||||||
MG at visit priorb | 1220 | 98 | (8.0) | 213 | 14 | (6.6) | 0.81 | (0.48, 1.36) | 0.73 | (0.44, 1.23) |
Secondary analyses | ||||||||||
MG status at enrollmentc | 1193 | 101 | (8.5) | 205 | 14 | (6.8) | 0.81 | (0.50, 1.30) | 0.76 | (0.47, 1.22) |
MG and BV status at visit priorb | 1220 | 213 | ||||||||
MG−, BV− | 768 | (63.0) | 143 | (67.1) | REF | REF | ||||
MG+, BV− | 43 | (3.5) | 8 | (3.8) | 1.04 | (0.57, 1.92) | 0.98 | (0.54, 1.76) | ||
MG−, BV+ | 354 | (29.0) | 56 | (26.3) | 0.84 | (0.63, 1.11) | 0.80 | (0.60, 1.07) | ||
MG+, BV+ | 55 | (4.5) | 6 | (2.8) | 0.57 | (0.25, 1.27) | 0.49 | (0.22, 1.09) |
A priori inclusion of age, study site, and frequency of condomless sex.
Mycoplasma genitalium at the visit prior and BV at the visit prior were time-varying.
N = 389 participants with MG sample at enrollment.
BV, bacterial vaginosis.